Drug Trial Radar · NCT05714514
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Apr 21, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Conditions
- Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase administered in the ConfIdeS studyDrug
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
Best available treatment administered in the ConfIdeS studyOther
Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients alive and free of dialysis at 3 yearsTime frame: 3 years after randomization in the ConfIdeS study
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) Hospital
Birmingham, Alabama
Cedars-Sinai Medical Center
Los Angeles, California
Northwestern University, Dept. General Surgery, Div. Transplantation
Chicago, Illinois
University of Chicago, Department of Surgery, Clinical Research Center
Chicago, Illinois
John Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Cooperman Barnabas Medical Center
Livingston, New Jersey
New York University (NYU) Langone Transplant Institute, NYU Langone Health
New York, New York
Columbia University
New York, New York
Houston Methodist Hospital
Houston, Texas
Methodist Hospital Specialty and Transplant
San Antonio, Texas
University of Washington Medical Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.